JACQUELYN DANESHFOROUZ: Open Payments
NPI 1649728775 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,808 in 93 payments from 14 companies in 2025. Trend: 2023 $2,616 · 2024 $2,825 · 2025 $4,808
Food & beverage: $3,008Consulting: $1,800
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 10 | $2,160 |
| Janssen Biotech, Inc. | 33 | $1,031 |
| Madrigal Pharmaceuticals | 17 | $781 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $174 |
| Ardelyx, Inc. | 5 | $153 |
| Boston Scientific Corporation | 1 | $144 |
| Celltrion USA Inc. | 4 | $100 |
| GlaxoSmithKline, LLC. | 1 | $60 |
| Aimmune Therapeutics, Inc. | 2 | $55 |
| ABBVIE INC. | 2 | $45 |
Products named: VELSIPITY, TREMFYA, REZDIFFRA, IBSRELA, General - Biliary Devices, ENTYVIO, VEGZELMA, XELJANZ.
Industry payments across NV — which companies pay providers there.
